About Informuta
Informuta makes a platform that forecasts whether bacteria will become resistant to an antibiotic during treatment. It maps mutational signatures across the whole genome and applies AI trained on long-running datasets. The same analysis detects resistance patterns that already exist. Informuta works with clinical microbiology labs, infectious disease pharmacists and antimicrobial stewardship programs.
Informuta was founded in New Orleans and spun out of Tulane University in 2023. Kalen Hall is cofounder and chief executive officer. Leo Williams is cofounder and principal scientist for bioinformatics. The company runs its central lab at the New Orleans BioInnovation Center and lists an office in San Diego. A peer-reviewed paper in Nature Communications covers Pseudomonas aeruginosa and reports 92-100% accuracy across two independent cohorts.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Nov 5, 2026 | $713,000of $2.0M target | 15 | $47,533 | DebtRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Informuta
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Mar 24, 2025 | Strategic investment | $125,000 | Tulane Ventures (lead) | Tulane Innovation Institute announcement ↗ |
Why Investors Backed Informuta
Informuta, Inc. builds a platform that forecasts whether bacteria will turn resistant to an antibiotic during a patient's treatment. It was founded in New Orleans and spun out of Tulane University in 2023. Federal grants and Louisiana investors have supported its work.
The problem it targets
Informuta's view is that the antimicrobial resistance crisis grows worse because diagnostic tools are limited and reactive. In its account, standard susceptibility testing shows which antibiotics seem effective when a sample is tested. That snapshot cannot show whether resistance will emerge during treatment, a risk that weighs most on high-acuity patients.
What the product does
The platform combines whole-genome sequencing, proprietary genomic biomarkers and AI to estimate future resistance risk. It is built to improve as it links bacterial evolution over time to real patient outcomes. Informuta's plan is to grow from diagnostics into an embedded layer that guides prescribing, stewardship and prevention.
Progress so far
Informuta published its proof of concept in Nature Communications, and prospective clinical studies are now under way. The National Science Foundation awarded a $275,000 STTR Phase I grant, then a $1.25 million SBIR Phase II grant in September 2026. Phase II work runs with the University of Pittsburgh Medical Center and the University of California, Irvine. Informuta opened a clinical lab at the New Orleans BioInnovation Center and expanded its partnership with Ochsner Health. It won the 2024 BioChallenge and added Ryan Shields as chief medical officer. Product launch with pilot health system partners is set for late 2026.
Who backs it
Tulane Ventures announced a $125,000 investment in Informuta in March 2025. Other funders include the New Orleans BioFund, 1834 Ventures, Boot64 Ventures and the Flamingo Funders. The National Science Foundation has funded the work through two grants. Tulane professors Zachary Pursell and Lisa Morici sit on the advisory board and co-invented the technology.
We wrote this summary from public statements by Informuta and its investors. It is not investment advice.
Informuta in the News
Leadership Team
Executive officers and directors listed on Informuta's Form D filed Nov 5, 2026.
